Ruth L. Coleman

3.7k total citations · 2 hit papers
60 papers, 1.9k citations indexed

About

Ruth L. Coleman is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Ruth L. Coleman has authored 60 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 24 papers in Cardiology and Cardiovascular Medicine and 10 papers in Surgery. Recurrent topics in Ruth L. Coleman's work include Diabetes Treatment and Management (26 papers), Diabetes Management and Research (19 papers) and Cardiovascular Function and Risk Factors (14 papers). Ruth L. Coleman is often cited by papers focused on Diabetes Treatment and Management (26 papers), Diabetes Management and Research (19 papers) and Cardiovascular Function and Risk Factors (14 papers). Ruth L. Coleman collaborates with scholars based in United Kingdom, United States and Canada. Ruth L. Coleman's co-authors include Rury R. Holman, Richard Stevens, Amanda Adler, Hertzel C. Gerstein, Timothy M. E. Davis, Rodney A. Hayward, Hisatomi Arima, Mark Woodward, Timothy E. Craven and Sophia Zoungas and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Ruth L. Coleman

54 papers receiving 1.8k citations

Hit Papers

Effects of intensive gluc... 2017 2026 2020 2023 2017 2024 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
    2017 367 citations Hertzel C. Gerstein, Rury R. Holman et al. profile →
  2. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
    2024 46 citations Amanda Adler, Ruth L. Coleman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruth L. Coleman United Kingdom 19 1.1k 625 392 260 249 60 1.9k
Peter C.Y. Tong Hong Kong 25 847 0.7× 314 0.5× 312 0.8× 382 1.5× 302 1.2× 38 2.0k
Sreenivasa Rao Kondapally Seshasai United Kingdom 12 1.0k 0.9× 691 1.1× 588 1.5× 305 1.2× 366 1.5× 21 2.2k
Mervete Miftaraj Sweden 20 1.9k 1.6× 869 1.4× 660 1.7× 328 1.3× 420 1.7× 49 2.8k
F. Travert France 12 1.2k 1.1× 366 0.6× 341 0.9× 178 0.7× 347 1.4× 20 1.7k
R Holman United Kingdom 5 959 0.8× 732 1.2× 250 0.6× 183 0.7× 124 0.5× 7 1.7k
Josef Coresh United States 15 1.1k 1.0× 693 1.1× 488 1.2× 329 1.3× 232 0.9× 25 2.5k
Janusz Gumprecht Poland 20 898 0.8× 258 0.4× 370 0.9× 168 0.6× 265 1.1× 152 1.6k
Ulrik Haagen Panton Denmark 9 971 0.8× 473 0.8× 312 0.8× 297 1.1× 405 1.6× 17 1.8k
Katarina Eeg‐Olofsson Sweden 29 1.8k 1.5× 581 0.9× 652 1.7× 302 1.2× 349 1.4× 85 2.5k
Rasmus Rørth Denmark 20 1.1k 1.0× 1.1k 1.8× 504 1.3× 225 0.9× 542 2.2× 63 2.4k

Countries citing papers authored by Ruth L. Coleman

Since Specialization
Citations

This map shows the geographic impact of Ruth L. Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth L. Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth L. Coleman more than expected).

Fields of papers citing papers by Ruth L. Coleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth L. Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth L. Coleman. The network helps show where Ruth L. Coleman may publish in the future.

Co-authorship network of co-authors of Ruth L. Coleman

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth L. Coleman. A scholar is included among the top collaborators of Ruth L. Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth L. Coleman. Ruth L. Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Golubić, Rajna, Ruth L. Coleman, Rustam Rea, et al.. (2025). Glucocorticoid‐induced hyperglycaemia in hospitalised adults: A matched cohort study (2013–2023). Diabetes Obesity and Metabolism. 27(7). 3635–3644.
2.
3.
4.
5.
Oulhaj, Abderrahim, Faisal Aziz, Nayyar Iqbal, et al.. (2023). Joint longitudinal and time‐to‐event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial. Diabetes Obesity and Metabolism. 25(5). 1261–1270. 2 indexed citations
6.
Wamil, Małgorzata, Ruth L. Coleman, Amanda Adler, John J.V. McMurray, & Rury R. Holman. (2021). Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. Diabetes Care. 44(8). 1877–1884. 35 indexed citations
7.
Lind, Marcus, Henrik Imberg, Ruth L. Coleman, Olle Nerman, & Rury R. Holman. (2021). Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 44(10). 2231–2237. 75 indexed citations
8.
Coleman, Ruth L., Alastair Gray, Uli C. Broedl, et al.. (2020). Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes Obesity and Metabolism. 22(7). 1151–1156. 12 indexed citations
9.
Juraschek, Stephen P., Jiun‐Ruey Hu, Anthony Ishak, et al.. (2020). Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine. 174(1). 58–68. 49 indexed citations
10.
Gerstein, Hertzel C., Ruth L. Coleman, Shishi Xu, et al.. (2020). Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care. 43(9). 2242–2247. 11 indexed citations
11.
Coleman, Ruth L., et al.. (2019). Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model. Diabetologia. 62. 1 indexed citations
12.
Maddaloni, Ernesto, Ruth L. Coleman, Paolo Pozzilli, & Rury R. Holman. (2019). Long‐term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obesity and Metabolism. 21(9). 2115–2122. 31 indexed citations
13.
Coleman, Ruth L., Aidan Gray, David Fitchett, et al.. (2017). Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?. Diabetic Medicine. 34. 23–23. 1 indexed citations
14.
Hayes, Alison, Philip Clarke, José Leal, et al.. (2011). An improved model to estimate lifetime health outcomes of patients with type 2 diabetes using 30-year follow-up data from the United Kingdom prospective diabetes study. Diabetologia. 54. 1 indexed citations
15.
Simmons, Rebecca K., Ruth L. Coleman, R R Holman, et al.. (2008). Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetologia. 51. 1 indexed citations
16.
Palmer, Andrew, Valentine Wn, P McEwan, et al.. (2007). 'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting'. Diabetes Care. 30(6). 1638–1646. 178 indexed citations
17.
Coleman, Ruth L., Richard Stevens, & R R Holman. (2007). Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine. Diabetic Medicine. 24. 56–56. 7 indexed citations
18.
Coleman, Ruth L., Richard Stevens, Matthews, & R R Holman. (2005). A Cardiovascular Risk Calculator for Type 2 Diabetes. Oxford University Research Archive (ORA) (University of Oxford). 54. 4 indexed citations
19.
Coleman, Ruth L., Richard Stevens, & R R Holman. (2005). Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation. Diabetologia. 48. 1 indexed citations
20.
Stevens, Richard, et al.. (2004). Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?. Diabetologia. 47. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter C.Y. Tong Breakdown of academic impact, for papers by Sreenivasa Rao Kondapally Seshasai Breakdown of academic impact, for papers by Mervete Miftaraj Breakdown of academic impact, for papers by F. Travert Breakdown of academic impact, for papers by R Holman Breakdown of academic impact, for papers by Josef Coresh Breakdown of academic impact, for papers by Janusz Gumprecht Breakdown of academic impact, for papers by Ulrik Haagen Panton Breakdown of academic impact, for papers by Katarina Eeg‐Olofsson Breakdown of academic impact, for papers by Rasmus Rørth
Rankless by CCL
2026